High Potency Active Pharmaceutical Ingredients Market Outlook 2031
The High Potency Active Pharmaceutical Ingredients Market was USD 25.17 Billion in 2022 and is likely to reach USD 43.25 Billion by 2031, expanding at a CAGR of 6.2% during 2023 – 2031. The growth of the market is attributed to the increasing incidence of cancer globally.
High potency active pharmaceutical ingredients are active substances that unveil biological activity at tremendously low concentrations. These are manufactured either provided to contract manufacturing organizations or in-house by the formulator company. Captive facility or in-house is generally opted by most of the companies in case of any exclusive drugs manufacturing.
The properties possessed by these anti-cancerous drugs such as effectiveness and minimum exposure of drug to the non-cancerous cell are some of the key factors. In addition, high potency active pharmaceutical ingredients are also used as antibody drug conjugates (ADCs). ADCs are the most important & effective treatment in combination with biologically active and monoclonal antibodies drug for the cancer.
For the treatment of cancer, several drugs are used but some of them are cytotoxic in nature and are dangerous to the non-cancerous cells, which may cause substantial damage to health. At the same time, the use of low efficacious drug is not effective in cancer treatment; hence, the targeted therapy method came into existence.
High Potency Active Pharmaceutical Ingredients Market Trends, Drivers, Restraints, and Opportunities
-
Wide number of cancer patients globally is a major driver expected to accelerate the growth of the market.
-
Rising expansion of the pharmaceutical & biotech industry and increasing investments in R&D activities in developing economies are expected to fuel the market growth.
-
Development of advanced anti-cancerous drugs for cancer treatment, which has less damage to the non-cancerous cell are the factor contributing to the market growth.
-
Advancement of multiple separation technology including purification, fermentation, and filtration processes with advanced technology to provide growth platform to this market in the coming years.
-
Some of pharmaceutical companies have made large investments in developing In-house capabilities and exclusive needs for In-house high potency active pharmaceutical ingredients investments. This is expected to boost the market growth.
-
Side effects of chemotherapy and effects on non-cancerous cells are expected to be a key restraint for the market growth.
Scope of High Potency Active Pharmaceutical Ingredients Market Report
The report on the global high potency active pharmaceutical ingredients market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
High Potency Active Pharmaceutical Ingredients Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Biotech and Synthetic), Manufacturers (Outsourced and In-house), Drug Types (Generic and Innovative), and Applications (Oncology, Hormonal, Glaucoma, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Pfizer Inc.; Sigma Aldrich Corporation; Eli Lilly and Company; Novartis International AG; Lonza Group; Teva Pharmaceutical Industries Ltd.; Roche Diagnostics; Bristol-Myers Squibb; Boehringer Ingelheim AG & Ko.; Covidien Plc.; Merck & Co., Inc.; Sanofi S.A.; BASF SE; Hospira Inc.; and Carbogen Amcis AG.
|
High Potency Active Pharmaceutical Ingredients Market Segment Insights
Biotech segment is expected to grow at a rapid pace
Based on products, the global high potency active pharmaceutical ingredients market is bifurcated into biotech and synthetic. The biotech segment accounted for a key share of the market in 2019 and is expected to grow at a rapid pace in the coming years owing to technology advancements and high efficacy. However, the synthetic segment is anticipated to expand at a healthy growth rate during the forecast period due to minimum side effects of the products used for the cancer treatment.
In-house segment is projected to expand at a considerable CAGR
On the basis of manufacturers, the market is segmented into outsourced and in-house. The in-house segment is projected to expand at a considerable CAGR during the forecast period owing to intensive capitalization by key players in the market. Meanwhile, the outsourced segment is anticipated to hold a large market share during the forecast period due to advancement in manufacturing technology.
Generic segment is expected to exhibit a robust growth rate
Based on drug types, the global high potency active pharmaceutical ingredients market is bifurcated into generic and innovative. The generic segment held a key share of the market in 2019 and is expected to exhibit a robust growth rate during the projected period due to the presence of unmet clinical needs and rising demand for the treatment drugs. However, the innovative segment is anticipated to constitute a major market share during the forecast period owing to favorable government initiatives and wide establishment of research and development activities.
Hormonal segment is expected to register a high CAGR
On the basis of applications, the market is segregated into oncology, hormonal, glaucoma, and others. The hormonal segment is expected to register a high CAGR during the projected period due to increased prevalence of metabolic disorders worldwide. On the other hand, the glaucoma segment is anticipated to grow significantly during the forecast period owing to growing obese population especially in developed countries.
North America is anticipated to constitute a key market share
In terms of regions, the global high potency active pharmaceutical ingredients market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America accounted for a key share of the market in 2019 and is anticipated to constitute a key market share in the coming years as the incidences of cancer is higher and wide expansion of the healthcare research projects in this region.
On the other hand, the market of Asia Pacific is expected to represent a large market share during the forecast period owing to growing pharmaceutical sector and increasing healthcare facilities in the region.
Segments
The global high potency active pharmaceutical ingredients market has been segmented on the basis of
Products
Manufacturers
Drug Types
Applications
- Oncology
- Hormonal
- Glaucoma
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Pfizer Inc.
- Sigma Aldrich Corporation
- Eli Lilly and Company
- Novartis International AG
- Lonza Group
- Teva Pharmaceutical Industries Ltd.
- Roche Diagnostics
- Bristol-Myers Squibb
- Boehringer Ingelheim AG & Ko.
- Covidien Plc.
- Merck & Co., Inc.
- Sanofi S.A.
- BASF SE
- Hospira Inc.
- Carbogen Amcis AG.
Competitive Landscape
Key players competing in the global high potency active pharmaceutical ingredients market are Pfizer Inc.; Sigma Aldrich Corporation; Eli Lilly and Company; Novartis International AG; Lonza Group; Teva Pharmaceutical Industries Ltd.; Roche Diagnostics; Bristol-Myers Squibb; Boehringer Ingelheim AG & Ko.; Covidien Plc.; Merck & Co., Inc.; Sanofi S.A.; BASF SE; Hospira Inc.; and Carbogen Amcis AG. The main market players are continuously engaged in various market development activities such as mergers, acquisitions, research and developments, and investments for innovative products and collaborations to expand their market positions.
Request For Customization
Enquiry Before Buying
Speak With Analyst
